MAPT and Alzheimer disease: Miren Ettecho and colleagues found that inhibition of Fyn by masitinib could efficiently ameliorate synaptic dysfunction and dendritic spine aberrances induced by Aβ and tau in AD (Ettcheto et al., 2021).